Associated Papers
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.
Deng F et al.
Cancers, 2026
Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.
Ghosh P et al.
Biochemical Society Transactions, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
Febres-Aldana CA et al.
Cancer Discovery, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Nakazawa S et al.
Cancer Discovery, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR et al.
Clinical and Translational Medicine, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.
Sattler M et al.
Cell Reports. Medicine, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Guérin C et al.
Biorxiv : the Preprint Server for Biology, 2025
Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.
Wang M et al.
Journal of Cancer Research and Clinical Oncology, 2025
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.
Lin H et al.
Communications Biology, 2025
Case Report: HGF and NF1 mutations as putative bypass mechanisms of MET inhibitor resistance in hepatocellular carcinoma: a case study.
Chen Z et al.
Frontiers in Pharmacology, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X et al.
Journal of Cancer Research and Clinical Oncology, 2024
Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy.
Bumpers QA et al.
Journal of Medicinal Chemistry, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL et al.
The Lancet. Oncology, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2024
Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion.
Dong SS et al.
Frontiers in Oncology, 2024
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala EEJ et al.
Current Research in Pharmacology and Drug Discovery, 2024
Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Schmalz L et al.
Lung Cancer (amsterdam, Netherlands), 2023
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U et al.
The Journal of Biological Chemistry, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.
Michaelides IN et al.
Journal of Medicinal Chemistry, 2023
Molecular Insights on the Conformational Transitions and Activity Regulation of the c-Met Kinase Induced by Ligand Binding.
Liu Z et al.
Journal of Chemical Information and Modeling, 2023
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R et al.
Cancers, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J et al.
Molecular Cancer Therapeutics, 2023
Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.
Xia H et al.
Cancer Medicine, 2023
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C et al.
Cancers, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M et al.
Molecular Cancer Therapeutics, 2022
Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients.
Shang Y et al.
Frontiers in Oncology, 2022
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
Tsai JM et al.
The Oncologist, 2021